Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with Abemaciclib.
Emily Nash SmythJulie BeyrerKimberly R SavernoElizabeth HaddenHamed AbedtashAngelo DeLucaGarreth W LawrenceSarah RybowskiPublished in: Drugs - real world outcomes (2022)
These real-world data complement clinical trial results by examining abemaciclib use among patients treated in routine clinical practice. The sizeable number of patients treated with prior CDK4 & 6i, chemotherapy, and/or visceral metastases at abemaciclib initiation suggest that many patients had very advanced disease and/or were in later stages of their treatment. These data confirm a higher percentage of patients treated with previous CDK4 & 6i than reported previously, reinforcing the importance of the ongoing, prospective clinical trials evaluating outcomes following progression on CDK4 & 6i.
Keyphrases
- clinical trial
- clinical practice
- metastatic breast cancer
- cell cycle
- newly diagnosed
- end stage renal disease
- electronic health record
- ejection fraction
- phase ii
- big data
- chronic kidney disease
- open label
- case report
- insulin resistance
- study protocol
- randomized controlled trial
- cell proliferation
- radiation therapy
- patient reported outcomes
- machine learning
- metabolic syndrome
- data analysis
- patient reported
- rectal cancer